1.
Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients. Biomol Biomed [Internet]. 2024 Oct. 17 [cited 2025 Feb. 15];24(6):1586–1594. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10528